KMT2A and leukemia: MM-102, MM-401, and MM-589, designed as inhibitors targeting the interaction of WDR5/MLL1, effectively inhibited histone H3K4 methyltransferase activity and reduced oncogenic gene transcription, inhibiting the growth and cell cycle of MLL-rearranged leukemia cells.